Are Incruse Ellipta and Trelegy Ellipta the Same Thing?
Incruse Ellipta (umeclidinium) Inhalation Powder and Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) are used to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Both Incruse Ellipta and Trelegy Ellipta contain anticholinergic drugs. Trelegy Ellipta also contains a corticosteroid and a selective long-acting beta2-adrenergic agonist (LABA).
Side effects of Incruse Ellipta and Trelegy Ellipta that are similar include cough and sore throat.
Side effects of Incruse Ellipta that are different from Trelegy Ellipta include upper respiratory infection, stuffy or runny nose, joint pain, muscle pain, tooth pain, stomach pain, bruising or dark areas of skin, chest pain, fast or irregular heartbeat, and constipation.
Side effects of Trelegy Ellipta that are different from Incruse Ellipta include headache, back pain, changes in taste, diarrhea, mouth pain, and gastroenteritis (nausea, vomiting, cramps, and fever).
Both Incruse Ellipta and Trelegy Ellipta may interact with other anticholinergic drugs.
Trelegy Ellipta may also interact with ketoconazole and other azole antifungals, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, diuretics, antiviral medications, conivaptan, nefazodone, and macrolide antibiotics.
What Are Possible Side Effects of Incruse Ellipta?
Common side effects of Incruse Ellipta include:
- upper respiratory infection,
- stuffy or runny nose,
- cough,
- sore throat,
- joint pain,
- muscle pain,
- tooth pain,
- stomach pain,
- bruising or dark areas of skin,
- chest pain,
- fast or irregular heartbeat, and
- constipation.
What Is Incruse Ellipta?
Incruse Ellipta (umeclidinium) Inhalation Powder is an anticholinergic drug used for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
What Is Trelegy Ellipta?
Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation is a combination of an inhaled corticosteroid (ICS), an anticholinergic, and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.
What Drugs Interact With Incruse Ellipta?
Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use. During pregnancy, Incruse Ellipta should be taken only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
What Drugs Interact With Trelegy Ellipta?
Trelegy Ellipta may interact with ketoconazole and other azole antifungals, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, beta-blockers, diuretics, antocholinergics, antiviral medications, conivaptan, nefazodone, and macrolide antibiotics. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Trelegy Ellipta; it is unknown how it would affect a fetus. It is unknown if Trelegy Ellipta passes into breast milk. Consult your doctor before breastfeeding.
How Should Incruse Ellipta Be Taken?
Incruse Ellipta (umeclidinium 62.5 mcg) should be administered as 1 inhalation dose once daily by the orally inhaled route only. Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use.
From 
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
www.incruse.com/?
GSK. Trelegy Ellipta Product Information.
www.trelegy.com/